MariTide
vs Retatrutide.
Compare MariTide and retatrutide by mechanism, studied schedule, trial stage, results, approval status, and the limits of cross-trial weight-loss comparisons.
Also searched as Maridebart cafraglutide vs Retatrutide · AMG 133 vs LY3437943 · monthly vs weekly injection
MariTide vs Retatrutide: What is the difference?
MariTide and retatrutide are different investigational obesity programs with no head-to-head trial. MariTide combines GLP-1 receptor agonism with GIP receptor antagonism in a long-acting peptide-antibody conjugate, while retatrutide activates GIP, GLP-1, and glucagon receptors in one molecule. MariTide has a monthly Phase 2 efficacy record and an active Phase 3 program. Retatrutide is a once-weekly program with Phase 3 topline results. Neither is FDA approved, and their headline percentages cannot establish which is more effective.
See the useful differences first.
Start with identity, current US status, trial coverage, and the evidence relationship. Then carry the exact pair into a country-aware workspace without losing either record.
MariTide
Investigational - not FDA approved
- Route
- Subcutaneous injection
- Registry
- 27 matched NCT records
- Sponsor
- Amgen
Retatrutide
Investigational - not FDA approved
- Route
- Once-weekly subcutaneous injection
- Registry
- 34 matched NCT records
- Sponsor
- Eli Lilly and Company
MariTide vs Retatrutide: how direct is the evidence?
No participant in the cited sources was randomized between MariTide and Retatrutide. Identity, mechanism, route, trial design, and regulatory status can be compared. Subtracting percentages from separate studies would create a treatment effect the evidence did not test.
MariTide
GLP-1 receptor agonist + GIP receptor antagonist
- Route
- Subcutaneous injection
- Stage
- Phase 3 program active
- Status
- Investigational - not FDA approved
Two evidence records, no shared randomization.
Treat percentages as separate source records. Do not subtract them, divide them into weekly rates, or use the larger value to name a winner.
No randomized head-to-head trialRetatrutide
GIP + GLP-1 + glucagon receptor agonist
- Route
- Once-weekly subcutaneous injection
- Stage
- Phase 3 program reporting results
- Status
- Investigational - not FDA approved
The current exact-intervention dataset contains 268 unique NCT records across 13 tracked investigational programs. Counts describe registry coverage, not comparative evidence strength.
matched NCT records
- Recruiting
- 6
- Results posted
- 2
- Recruiting site observations
- 1581
matched NCT records
- Recruiting
- 2
- Results posted
- 2
- Recruiting site observations
- 450
Compare the named molecules, active components, sponsors, and receptor strategies.
Compare the studied route, frequency, development phase, and exact program record.
Compare exact approvals, applications, and investigational status in the jurisdiction being checked.
Treat percentages as separate source records. Do not subtract them, divide them into weekly rates, or use the larger value to name a winner.
Use only adverse-event evidence reported for the cited protocol. Separate studies cannot establish which program is safer.
No group result, receptor count, route, approval milestone, or chart position predicts the best choice for one person.
Check both programs in the same market.
Approval, trial activity, product registration, pharmacy rules, and seller authority are country specific. Open both records before treating a status from one market as valid in another.
Answer the question without inventing a winner.
Each answer keeps route, mechanism, development stage, and trial result attached to the evidence that produced the fact.
Is MariTide better than Retatrutide?
No head-to-head evidence establishes MariTide as better than Retatrutide. MariTide's clearest differentiator is a monthly lead schedule in its clinical program, while Retatrutide is studied as a once-weekly injection and has reported Phase 3 obesity results. Their efficacy percentages come from different phases, durations, doses, populations, and analysis methods, so they cannot identify a clinical winner.
Is MariTide monthly or quarterly?
Monthly dosing has the clearest efficacy record. Quarterly dosing has been studied as continued maintenance among selected participants who had already achieved substantial weight loss during earlier MariTide treatment. That does not establish quarterly initiation, an approved dosing schedule, or that patients maintained the same result after stopping treatment.
MariTide
GLP-1 receptor agonist + GIP receptor antagonist
- Route
- Subcutaneous injection
- Stage
- Phase 3 program active
- Status
- Investigational - not FDA approved
- Featured trial anchors
- NCT05669599 · NCT06858878 · NCT07037433
Retatrutide
GIP + GLP-1 + glucagon receptor agonist
- Route
- Once-weekly subcutaneous injection
- Stage
- Phase 3 program reporting results
- Status
- Investigational - not FDA approved
- Featured trial anchors
- NCT05929066 · NCT05931367 · NCT05882045
Compare the field, then read the limit.
The search is usually trying to resolve two distinct questions at once: whether less-frequent administration could reduce treatment burden, and whether a larger reported trial percentage means a stronger drug. The current evidence can describe schedule, mechanism, trial population, and development stage. It cannot rank the programs because the studies used different durations, doses, populations, and analysis methods.
| Field | MariTide | Retatrutide | How to interpret it |
|---|---|---|---|
| Mechanism | GLP-1 receptor agonist plus GIP receptor antagonist | GIP, GLP-1, and glucagon receptor agonist | The programs engage different receptor strategies. Mechanism alone does not predict a clinical winner. |
| Schedule studied | Monthly lead schedule; quarterly maintenance studied in selected participants | Once-weekly subcutaneous injection | A studied schedule is not an approved dose, and maintenance is not the same as initiation. |
| Evidence anchor | Up to 19.9% at week 52 in Phase 2 under an efficacy estimand | 28.3% at week 80 in TRIUMPH-1 under an efficacy estimand | Different trial phases, durations, doses, and populations prevent a fair percentage ranking. |
| Current record | Phase 3 program active | Phase 3 program reporting results | Both remain investigational despite advanced clinical development. |
Why the headline numbers do not name a winner.
MariTide's quarterly evidence concerns continued maintenance treatment in selected Phase 2 participants after substantial prior loss. It is not a proven quarterly starting schedule. Retatrutide's 28.3% figure comes from the 12 mg TRIUMPH-1 arm at 80 weeks under an efficacy estimand. Placing those facts in one row is useful for orientation, but it does not create a randomized comparison.
Keep the comparison honest.
- 01
Keep MariTide's monthly efficacy result separate from its exploratory lower-frequency maintenance evidence.
- 02
Attach every weight-loss percentage to the study duration, population, dose, comparator, and estimand that produced it.
- 03
Do not interpret an online product using either development name as the material studied in a sponsor's clinical trial.
A country-specific approval, clinical trial, or matching name does not authenticate an online product or establish access elsewhere. This page contains no treatment recommendation, buying route, personal-use protocol, or affiliate link.
Open the safety and status guide →